EUVIMEDEUVIMED entdecken
Crossref

Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients

Jérôme Dumortier, Olivier Boillot

Transplant Immunology · 2024

DOI: 10.1016/j.trim.2024.102014 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplant Immunology, 2024. Verfasst von Jérôme Dumortier und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Digestive Diseases, Edouard Herriot Hospital, and University of Lyon 1 Claude Bernard, Lyon, France. Electronic address: jerome.dumorti…. Hauptthemen laut MEDLINE: Liver Transplantation, Organ Transplantation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: After organ transplantation, strategies for simplifying the therapeutic regimen may improve adherence and prevent acute organ rejection and/or late graft loss. The present study aimed to evaluate the safety and efficacy of conversion from everolimus (EVR) twice daily to sirolimus (SIR) once daily in a large cohort of liver transplantation (LT) patients. METHODS: We included 108 LT patients with at least 12 months of post-transplant follow-up and no rejection episodes in the last year. Conversion was based on a 1:1 ratio (but eventually adapted to available formulations of SIR). RESULTS: The median age at the time of conversion was 68.9 years (range: 26.1-83.6); 75.0% were men. The main indications for mTOR inhibitor use were renal failure (38.9%) and/or a history of malignancy (37.0%). Median conversion time after LT was 14.8 years (range: 2.3-31.5). The median dose of EVR and SIR (initially) was 1.50 mg/day (range: 0.5-4.5). The mean follow-up after conversion was 15.8±4.4 months. Median serum EVR/SIR trough levels before/after conversion were 3.85 ng/mL vs. 6.32 ng/mL (p < 0.05), i.e. a 1:1.64 ratio. At the end of follow-up after conversion, the median dose of SIR was 1.25 mg/day (range: 0.5-3.5), and the mean serum SIR trough level was 5.23 ng/mL; 9 patients (8.3%) had returned to EVR, because of side effects (mainly digestive), that resolved thereafter. No biopsy-proven acute rejection episode was observed. Finally, 87.1% of patients considered the conversion beneficial and the cost was reduced by 50.3%. CONCLUSION: The results of our study indicate that conversion from once-daily EVR to once-daily SIR in stable LT patients is safe, but needs dose adaptations and careful monitoring.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Liver TransplantationOrgan TransplantationMaleHumansAdultMiddle AgedAgedAged, 80 and overFemaleEverolimusSirolimusImmunosuppressive AgentsGraft RejectionTacrolimusTransplant Recipients

Stichwörter der Autor:innen

ConversionCostEverolimusLiver transplantationQuality of lifeSirolimusmTOR inhibitors

Substanzen

EverolimusSirolimusImmunosuppressive AgentsTacrolimus

Autor:innen und Institutionen

  • Department of Digestive Diseases, Edouard Herriot Hospital, and University of Lyon 1 Claude Bernard, Lyon, France. Electronic address: jerome.dumortier@chu-lyon.fr.
  • Department of Digestive Diseases, Edouard Herriot Hospital, and University of Lyon 1 Claude Bernard, Lyon, France.

Zitieren

APA

Dumortier, J., & Boillot, O. (2024). Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients. Transplant Immunology. https://doi.org/10.1016/j.trim.2024.102014

Vancouver

Dumortier J, Boillot O. Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients. Transplant Immunology. 2024. doi:10.1016/j.trim.2024.102014

BibTeX
@article{Dumortier2024,
  author = {Dumortier, Jérôme and Boillot, Olivier},
  title = {Conversion from twice-daily everolimus to once-daily sirolimus in long-term stable liver transplant recipients},
  journal = {Transplant Immunology},
  year = {2024},
  doi = {10.1016/j.trim.2024.102014}
}
Kostenlos starten →